Nanomolar small molecule inhibitors for ανβ6, ανβ5, and ανβ3 integrins

Journal of Medicinal Chemistry

Volumn 45, Issue 5, 2002, Pages 1045-1051

  Goodman, Simon L ^a   Hölzemann, Günter ^a   Sulyok, Gäbor A G ^b   Kessler, Horst ^b  

^a MERCK KGAA   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; CYCLOPEPTIDE; FIBRINOGEN; FIBRONECTIN; GLUTARIC ACID DERIVATIVE; INTEGRIN; INTEGRIN RECEPTOR; NANOPARTICLE; PENTAPEPTIDE; SYNTHETIC PEPTIDE; TENASCIN; VITRONECTIN;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LIGAND BINDING; PEPTIDE SYNTHESIS; PROTEIN BINDING; SIGNAL TRANSDUCTION;

AMINO ACIDS; ANTIGENS, NEOPLASM; CELL ADHESION; EXTRACELLULAR MATRIX; FIBRONECTINS; GLUTARATES; GUANIDINES; HUMANS; INTEGRINS; MOLECULAR MIMICRY; PEPTIDES; PYRIDINES; RECEPTORS, VITRONECTIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037186502     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0102598     Document Type: Article

References (55)

1. Integrins: Versatility, modulation, and signaling in cell adhesion
2. Monoclonal antibody characterization of two distant sites required for function of the central cell-binding domain of fibronectin in cell adhesion, cell migration, and matrix assembly
3. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors
4. Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist
5. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp
6. Potent, selective, orally active 3-Oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists
7. Discovery of potent nonpeptide vitronectin receptor antagonists
8. Design, synthesis and biological evaluation of nonpeptide integrin antagonists
9. Novel solid-phase synthesis of azapeptides and azapeptoides via Fmoc-strategy and its application in the synthesis of RGD-mimetics
10. Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis
11. ανβ3 integrin binding affinity and specificity of SM256 in various species
12. Nonpeptidic ανβ3 integrin antagonist libraries: On-bead screening and mass spectrometric identification without tagging
13. Solid-phase synthesis of a nonpeptide RGD Mimetic Library: New selective ανβ3 integrin antagonists
14. Recent advances in ανβ3 integrin inhibitors
15. Selective, tight-binding inhibitors of integrin ta4pl that inhibit allergic airway responses
16. A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of Streptococcus pyogenes by blocking formation of integrin α5β1-fibronectin-M1 protein complexes
17. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship ofpeptides corresponding to the carboxy-terminal segment of the γ-chain
18. Investigation of conformational specificity at GPIIb/IIIa: Evaluation of conformationally constrained RGD peptides
19. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1
20. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides
21. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin ανβ3 antagonists
22. Type II′ to Type I P3-turn swap changes specificity for integrins
23. Synthesis and solution conformation of cyclo[RGDRGD]: A cyclic peptide with selectivity for the ανβ3 receptor
24. A novel RGD containing dodecapeptidomimetic which exhibits selective binding to the ανβ3 receptor
25. N-methylated cyclic RGD peptides as highly active and selective ανβ3 integrin antagonists
26. Definition of an unexpected ligand recognition motif for ανβ6 integrin
27. Isolation of a highly specific ligand for the α5β1 integrin from a phage display library
28. Inactivation of the integrin β6 subunit gene reveals a role of epithelial integrins in regulating inflammation in the lung and skin
29. The ανβ6 integrin promotes proliferation of colon carcinoma cells through a unique region of the β6 cytoplasmic domain
30. Expression of the β6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling
31. Reepithelialization of normal human excisional wounds is associated with a switch from ανβ5 to ανβ6 integrins
32. Keratinocytes in human wounds express ανβ6 integrin
33. The integrin ανβ6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin
34. Integrin-mediated signaling of gelatinase B secretion in colon cancer cells
35. The ανβ6 integrin induces gelatinase B secretion in colon cancer cells
36. The integrin ανβ6 binds and activates latent TGF-β1: A mechanism for regulating pulmonary inflammation and fibrosis
37. Structure and function of platelet aIIb33
38. Tumor angiogenesis and the role of vascular cell integrin ανβ 3
39. Inhibition ofneointimal hyperplasia by blocking ανβ3 integrin with a small peptide antagonist Gpen-GRGDSPCA
40. Definition of two angiogenic pathways by distinct αν integrins
41. Transmembrane-truncated ανβ3 integrin retains high affinity for ligand binding: Evidence for an 'inside-out' suppressor?
42. An anti-αν-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice
43. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the ανβ3 integrin for a new cancer therapy
44. Synthesis and Conformational Studies of N-methylated Cyclic RGD-peptides
45. A peptidomimetic antagonist of the integrin ανβ3 inhibits leyding cell tumor growth and the development of hypercalcemia of malignancy
46. Demonstration of nonlinear detection in ELISA resulting in up to 1000-fold too high affinities of fibrinogen binding to integrin αIIbβ3
47. Peptide conformations, 19. Conformation and biological activity of cyclic peptides
48. Requirement of Vascular integrin ανβ3 for angiogenesis
49. Requirement of the NPXY motif in the integrin β3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo
50. Integrin ανβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels